Sihuan Pharmaceutical Holdings Group Ltd (0460:HK) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Sihuan Pharmaceutical Holdings Group Ltd stock forecast from 0 analysts, the average analyst target price for Sihuan Pharmaceutical Holdings Group Ltd is not available over the next 12 months. Sihuan Pharmaceutical Holdings Group Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Sihuan Pharmaceutical Holdings Group Ltd is Bearish, which is based on 3 positive signals and 9 negative signals. At the last closing, Sihuan Pharmaceutical Holdings Group Ltd’s stock price was HKD 0.51. Sihuan Pharmaceutical Holdings Group Ltd’s stock price has changed by -8.93% over the past week, -12.07% over the past month and -39.29% over the last year.
No recent analyst target price found for Sihuan Pharmaceutical Holdings Group Ltd
No recent average analyst rating found for Sihuan Pharmaceutical Holdings Group Ltd
Company Overview Sihuan Pharmaceutical Holdings Group Ltd
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China. It offers drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology and technology promotion, and medical aesthetic research and development services. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong. Address: Office Tower, Convention Plaza, Wan Chai, Hong Kong Read Less
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China. It offers drugs in the oncology, metabolism, dia...Read More
Frequently Asked Questions About Sihuan Pharmaceutical Holdings Group Ltd (0460:HK) Stock
Stock Target Advisor's fundamental analysis for Sihuan Pharmaceutical Holdings Group Ltd's stock is Bearish.
0460:HK stock's dividend yield is 7.40%.
Our analysis grades 0460:HK stock's dividend yield at C+. This means that 0460:HK stock's dividend yield is above 79% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 0460:HK may be a average dividend stock for its sector.
Unfortunately we do not have enough data on 0460:HK's stock to indicate what its average analyst target is.
0460:HK stock's Price/Earning ratio is 23.89.
Our analysis grades 0460:HK stock's Price / Earning ratio at F. This means that 0460:HK stock's Price/Earning ratio is above 81% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 0460:HK may be a overvalued for its sector.
The last closing price of 0460:HK's stock was HKD 0.51.
The most recent market capitalization for 0460:HK is HKD 4.66B.
Unfortunately we do not have enough analyst data on 0460:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sihuan Pharmaceutical Holdings Group Ltd's stock.
As per our most recent records Sihuan Pharmaceutical Holdings Group Ltd has 2,872 Employees.
Sihuan Pharmaceutical Holdings Group Ltd's registered address is Convention Plaza, Wan Chai, Hong Kong.
You can get more information about it from Sihuan Pharmaceutical Holdings Group Ltd's website at https://www.sihuanpharm.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 0460:HK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
